跳至主要内容
临床试验/NCT00754039
NCT00754039已完成4 期

The Effects of the Combination of Welchol and Tricor Compared to TriCor Alone in Patients With Mixed Hyperlipidemia

Daiichi Sankyo0 个研究点目标入组 129 人开始时间: 2003年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
129
主要终点
% change in LDL-C from baseline

研究概览

简要总结

The primary objective of this study is to compare the effect of Welchol in combination with TriCor compared to TriCor alone on low-density lipoprotein cholesterol (LDL-C) in patients with high cholesterol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 30-70 years of age
  • History of mixed hyperlipidemia
  • Prescribed a Step 1 diet at least 30 days prior to screening
  • Women were not pregnant, breast-feeding, or plan to become pregnant during the study
  • Women had a hysterectomy or tubal ligation, were post-menopausal, or practiced reliable birth control procedures
  • Serum LDL-C >/= 115 mg/dL; Serum TG >/= 150 & < 750 mg/dL

排除标准

  • HbA1C > 10%
  • Type 1 diabetes
  • Intolerance to fibrates
  • History of intolerance to colesevelam HCl
  • History of swallowing disorders or intestinal motility disorders
  • Any other disorder that might interfere with the conduct of the study
  • History of drug or alcohol abuse
  • Recent (within 28 days) history of cardiac disease (MI, CHF, CABG, etc.)

研究组 & 干预措施

1

Experimental

Welchol + TriCor

干预措施: colesevelam HCl tablets and fenofibrate tablets (Drug)

2

Placebo Comparator

Welchol + placebo

干预措施: fenofibrate tablets and Welchol placebo tablets (Drug)

结局指标

主要结局

% change in LDL-C from baseline

时间窗: 6 weeks

次要结局

  • The absolute change in LDL-C from baseline(6 weeks)
  • The absolute change and % change in LDL-C from week -8 (untreated)(14 weeks)
  • The percentage of patients who achieved target LDL-C(6 Weeks)

研究者

申办方类型
Industry

相似试验